Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
Active, not recruiting · NCT03978624 · Registry updated 2025-10-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Active, not recruiting | Phase 2 | 2025-10-15 | NCT03978624 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Merck Sharp & Dohme LLC | 650 |
| Syndax Pharmaceuticals | 16 |
| UNC Lineberger Comprehensive Cancer Center | 125 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fox Chase Cancer Center | Philadelphia | United States | 259 |
| Lineberger Comprehensive Cancer Center | Chapel Hill | United States | 15 |